The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) continued its decrease from the past few weeks by going down 2.78 decrease over the last five trading days and traded at 3,211.31 points. The Index is up 15.82 percent year-to-date.
Last week the Investing News Network (INN) reported on FibroGen’s (NASDAQ:FGEN) massive increase in its stock value due to positive trial data idiopathic pulmonary fibrosis (IPF) drug pamrevlumab. As part of second quarter release season, Valeant Pharmaceuticals shared its sales stream totaled $2.23 billion, BioPharma DIVE reported the company has been facing manufacturing and legal troubles causing its decline this year. FiercePharma reported Mylan (NASDAQ:MYL) received subpoena from the Department of Justice looking into their opioid business. According to the report Mylan called the subpoena as “seeking informaion relating to opioids manufactured, marketed or sold by” the company from 2013 up until 2016.
AVEO Pharmaceuticals (NASDAQ:AVEO)
Staar Surgical (NASDAQ:STAA)
PDL BioPharma (NASDAQ:PDLI)
Natural Alternatives (NASDAQ:NAII)
AVEO is a biopharmaceutical company working on the development of oncology therapeutics. Last week the company released their financial results for the second quarter of 2017 in which it highlighted its recent advancements in upcoming trials and the recommendation of approval for tivozanib for advanced renal cell carcinoma.
AVEO Pharmaceuticals gained 15.02 percent last week and closed the week at $2.91 per share.
Staar develops implementable lenses for the eye to eliminate the need of glasses and contact lenses. Last week Staar also released their second quarter financial results in which their quarterly net sales went up 5 percent from last year to a total of $21.9 million, with only a reported $0.01 loss per share.
Staar Surgical gained 12.98 percent last week and closed the week at $11.75 per share.
Vericel is a company with cell-based therapies, with three specific products in the US: MACI (autologous cultured chondrocytes on porcine collagen membrane), Carticel (autologous cultured chondrocytes), Epicel (cultured epidermal autografts). As part of their financial disclosure, the company reported $9.3 million in gross profits.
Vericel gained 12.90 percent last week and closed the week at $3.50 per share.
PDL acquires and manages a portfolio of companies and products in the biotech, pharmaceutical and medical device sectors. The company also released their financial returns for the second quarter, with revenues totaling $143.8 million.
PDL BioPharma gained 11.72 percent last week and closed the week at $2.67 per share.
Natural Alternatives is a formulator and manufacturer of customized nutritional supplements. The company was featured in several market blogs for its increase in stock activity on August 11. However, there haven’t been any other news to cause the stock increase.
Natural Alternatives gained 7.48 percent last week and closed the week at $10.48 per share.
Don’t forget to follow @INN_LifeScience for real-time updates!
Data for 5 Top NASDAQ Stocks articles is retrieved each Friday after market close using The Globe and Mail’s market data filter. Only companies with a market capitalization greater than $10 million prior to the week’s gains are included. Companies within the biotechnology and pharmaceutical sectors are considered.
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.